If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSchroder Japan Regulatory News (SJG)

Share Price Information for Schroder Japan (SJG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 260.00
Bid: 259.00
Ask: 262.00
Change: 2.00 (0.78%)
Spread: 3.00 (1.158%)
Open: 261.00
High: 261.00
Low: 259.00
Prev. Close: 258.00
SJG Live PriceLast checked at -
Schroder Japan Growth is an Investment Trust

To achieve capital growth from an actively managed portfolio principally comprising securities listed on the Japanese stock markets.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kepler Trust Intelligence: New Research

12 Sep 2019 07:05

RNS Number : 0209M
SchroderJapan Growth Fund PLC
12 September 2019
 

Schroder Japan Growth: New research

12/09/2019

Despite clear continuity, a recent manager change has seen this trust move to a wide discount versus peers...

Read more

Schroder Japan Growth (SJG) invests in Japanese equities with a bottom-up process, aiming to generate long term capital growth. The trust typically has a bias towards 'value' stocks and currently has the highest exposure to this style of any trust in the AIC Japan sector.

The process centres on the identification of under-valued companies through superior fundamental research carried out by a team of 11 analysts on the ground in Tokyo, including three specialising in the under-researched Japanese small-cap market. The manager, Masaki Taketsume, is based in London, having taken over from Andrew Rose in July 2019. However, he had been co-manager since 2017 and previously worked in the analyst team in Tokyo from 2007, so there is total continuity of approach.

Although the process centres on valuation, a key differentiator from its peers, quality and growth characteristics are considered when the team build Fair Value models for each stock. The trust also has a structural overweight to small and mid caps. Masaki believes that this exploits the advantage of the deep in-house analyst team at Schroders, which is a particular benefit in Japanese small caps given the low levels of sell-side analyst coverage in Japan.

The value bias has not helped the fund in recent years, when 'growth' stocks have been dominant, and it has underperformed as growth and momentum-focused trusts have done better. The portfolio has tended to be overweight in more cyclical areas of the market which have been out of favour relative to the steadier growth sectors, although Masaki has moderated the cyclical tilt in recent months.

In recent years the discount has been wider than the sector average, which we would attribute to the value approach being out of favour and, more recently, it widened after the announcement of the change of manager - though we understand there is very little change to the investment process or style. The discount has widened to 15.2% this year compared to a sector average of 6.2%.

The value tilt means the trust has a reasonable yield for Japan, which has traditionally been a low-yielding market. On the current share price the yield is 2.2%, with the trust having grown its dividend by 20% a year over the last five years. Dividend growth in Japan is being supported by improving corporate governance thanks to government-led reforms.

The company has structural gearing maturing in 2022 worth 12% of NAV at current levels. This increases the share price's sensitivity to market movements.

Click here to read the full report

 

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

 

Important information

Schroder Japan Growth is a client of Kepler Trust Intelligence. This material should be considered a marketing communication, and is not independent research.

Kepler Partners is not authorised to make recommendations to Retail Clients. This report is based on factual information only, and is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

This report has been issued by Kepler Partners LLP solely for information purposes only and the views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment. If you are unclear about any of the information on this website or its suitability for you, please contact your financial or tax adviser, or an independent financial or tax adviser before making any investment or financial decisions.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. Persons who access this information are required to inform themselves and to comply with any such restrictions. In particular, this website is exclusively for non-US Persons. The information in this website is not for distribution to and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States of America to or for the benefit of US Persons.

This is a marketing document, should be considered non-independent research and is subject to the rules in COBS 12.3 relating to such research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not to be taken as advice to take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's conflict of interest policy is available on request.

Past performance is not necessarily a guide to the future. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that Independent financial advice should be taken before entering into any financial transaction.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is a limited liability partnership registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority.

 

 

About this service

Kepler Trust Intelligence for private investors is not just another news and research website. Our aim is to create a library of high quality investment strategy research, fund analysis and useful guides for private investors, all written in-house by experienced analysts on the investment companies team at Kepler Partners.

We are focused entirely on investment trusts, however we believe that it helps to understand them better if they are placed on a level playing field with OEICs, so you will see comparisons between the two in these pages often.

 

Our content falls into three categories;

Investment strategy articles are designed to highlight opportunities and developments which are of interest to investment trust investors, positive or negative.

Fund research focuses on individual trusts, examining them in detail to create a snapshot picture which you can use to decide whether or not you want to invest in them.

Educational output is split into simple guides, designed to help beginners understand how investment trusts work, and more complex guides to sectors, regions and strategies which may be of interest to investors.

We do not produce massive amounts of research. Our focus is on quality, not quantity, so we are unlikely to publish more than four or five articles in a given week. For this reason we recommend that you join our mailing list, and we'll send you an email once a week alerting you to what's new on the site. We won't sell your details, and we won't spam you with useless updates.

 

How are we funded?

Kepler Trust Intelligence is funded entirely by the providers of investment trusts, and is made available freely to any person (professional or private individual) who wants to access it. We clearly disclose all of our relationships, but our research is either paid for directly by specific trusts and their boards, or more generally by the larger asset management groups who pay to have adverts and advertorial. As a result, all of our research should be considered "non-independent" and readers should consider it as marketing.

All of our content is freely available to anyone. We run two versions of the site - one for professionals and one for private investors. The professional site requires readers to volunteer the name of the company they work for and the city / region - so that from a compliance perspective we can be satisfied that all readers really are a professional.

 

We provide information, not advice

While we hope that you find the research we publish useful, and we believe it will help you to make a more informed decision, but we must of course stress that none of the research published here constitutes a recommendation, or advice, and you should not think that - just because we've published a report on a trust - we believe that trust is a 'buy'. Please read our terms and conditions.

 

If you want to manage your own investments we hope that this website is a useful source of information which helps you to do that, however if you are in any doubt, you should speak to a financial adviser.

 

Pascal Dowling

 

Kepler Partners

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAEALNFFFANEFF
Date   Source Headline
10th May 20245:19 pmRNSTransaction in Own Shares
10th May 202410:30 amRNSNet Asset Value(s)
9th May 20245:29 pmRNSTransaction in Own Shares
9th May 202410:47 amRNSNet Asset Value(s)
8th May 202410:50 amRNSNet Asset Value(s)
7th May 202410:40 amRNSNet Asset Value(s)
3rd May 202410:59 amRNSNet Asset Value(s)
2nd May 20245:11 pmRNSTransaction in Own Shares
2nd May 202410:48 amRNSNet Asset Value(s)
1st May 20245:17 pmRNSTransaction in Own Shares
1st May 20243:07 pmRNSPortfolio Update
1st May 202410:42 amRNSNet Asset Value(s)
30th Apr 20245:15 pmRNSTotal Voting Rights
30th Apr 202411:35 amRNSTransaction in Own Shares
30th Apr 202410:22 amRNSNet Asset Value(s)
29th Apr 202410:25 amRNSNet Asset Value(s)
26th Apr 20245:20 pmRNSTransaction in Own Shares
26th Apr 202410:48 amRNSNet Asset Value(s)
25th Apr 202410:47 amRNSNet Asset Value(s)
24th Apr 202410:29 amRNSNet Asset Value(s)
23rd Apr 202411:11 amRNSNet Asset Value(s)
22nd Apr 202410:38 amRNSNet Asset Value(s)
22nd Apr 20247:00 amRNSResults analysis from Kepler Trust Intelligence
19th Apr 202410:18 amRNSNet Asset Value(s)
18th Apr 202410:19 amRNSNet Asset Value(s)
17th Apr 202410:39 amRNSNet Asset Value(s)
17th Apr 20247:00 amRNSHalf-year Report
16th Apr 202410:37 amRNSNet Asset Value(s)
15th Apr 20244:14 pmRNSPortfolio Update
15th Apr 202411:42 amRNSNet Asset Value(s)
12th Apr 202411:07 amRNSNet Asset Value(s)
11th Apr 202410:37 amRNSNet Asset Value(s)
10th Apr 202410:28 amRNSNet Asset Value(s)
9th Apr 202411:08 amRNSNet Asset Value(s)
8th Apr 202411:23 amRNSNet Asset Value(s)
5th Apr 202410:28 amRNSNet Asset Value(s)
4th Apr 202411:04 amRNSNet Asset Value(s)
3rd Apr 202410:38 amRNSNet Asset Value(s)
2nd Apr 20241:51 pmRNSHolding(s) in Company
2nd Apr 202411:13 amRNSNet Asset Value(s)
28th Mar 20245:08 pmRNSTotal Voting Rights
28th Mar 202411:19 amRNSNet Asset Value(s)
27th Mar 202411:00 amRNSNet Asset Value(s)
26th Mar 202411:31 amRNSNet Asset Value(s)
25th Mar 202411:25 amRNSNet Asset Value(s)
22nd Mar 20244:59 pmRNSHolding(s) in Company
22nd Mar 202410:35 amRNSNet Asset Value(s)
21st Mar 202410:24 amRNSNet Asset Value(s)
20th Mar 202410:37 amRNSNet Asset Value(s)
19th Mar 202410:45 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.